#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Gaucher's disease type I Astrocytoma Loss of consciousness Waldenstrom's macroglobulinaemia refractory Neuroendocrine cell hyperplasia of infancy Paraneoplastic neurological syndrome Mixed-type liposarcoma Neutropenia Nasopharyngeal cancer Autoimmune myositis Peritoneal neoplasm B-cell small lymphocytic lymphoma recurrent Pleural mesothelioma malignant Skin angiosarcoma Growth hormone deficiency More trials…

    Learn about Rare Diseases

    Myelodysplastic syndrome with excess blasts – Diagnostics Progressive supranuclear palsy – Diagnostics Testicular leiomyosarcoma – Basic Information VEXAS syndrome – Diagnostics VEXAS syndrome – Basic Information Familial haemophagocytic lymphohistiocytosis – Basic Information Rhabdoid tumour – Life with Disease Congenital nephrogenic diabetes insipidus – Basic Information IgA nephropathy – Basic Information Lennox-Gastaut syndrome – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Azenosertib Db-Oto-5 Cefazolin Favezelimab The-630 AB521 Alnus Glutinosa Pollen Atazanavir YL201 OXYBUTYNIN HYDROCHLORIDE Mometasone Furoate Dyp688 ACICLOVIR SODIUM Timolol Io103 Acetate Iobitridol Pralatrexate Epinephrine Io102 Hydrochloride Digitoxin More therapies…

    Learn about Your Condition

    Palpitations Peripheral artery restenosis Hodgkin's disease refractory Desmoplastic melanoma Breast cancer stage III Von Hippel-Lindau disease Sarcoma Malignant lymphoid neoplasm Hepatitis B Anal abscess Hyperhidrosis Alagille syndrome Hydrocele Bronchopulmonary dysplasia Colorectal cancer metastatic More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Pulmonary fibrosis

  • A study to evaluate the effectiveness of BI 1015550 in people with lung abnormalities and a family history of pulmonary fibrosis

    Recruiting

    3 1
    Investigated Diseases:
    • Interstitial lung disease
    Investigated Drugs:
    • 1-[[(5R)-2-[4-(5-Chloro-2-Pyrimidinyl)-1-Piperidinyl]-6,7- Dihydro-5-Oxidothieno[3,2-D]Pyrimidin-4- Yl]Amino]-Cyclobutanemethanol
    • Bi 1015550
    Belgium France Germany Italy The Netherlands Spain

  • Long-Term Safety Study of Inhaled Pirfenidone for Patients with Progressive or Idiopathic Pulmonary Fibrosis

    Recruiting

    2 1 1
    Investigated Diseases:
    • Pulmonary fibrosis
    • Idiopathic pulmonary fibrosis
    Investigated Drugs:
    • Pirfenidone
    Czechia France Germany Italy The Netherlands Poland +1

  • Study on the Effects of Inhaled Treprostinil for Patients with Progressive Pulmonary Fibrosis

    Recruiting

    3 1
    Investigated Drugs:
    • Treprostinil
    Belgium France Germany Italy Spain

  • Study on PET/CT Imaging with [18F]-AlF-FAPI-74 for Identifying Fibrosis and Inflammation in Patients with Progressive Pulmonary Fibrosis

    Recruiting

    1 1 1
    Investigated Drugs:
    • [Al[18F]F]Fapi-74
    The Netherlands

  • Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis

    Not yet recruiting

    3 1 1
    Investigated Drugs:
    • ADMILPARANT
    Austria Belgium Denmark Finland France Germany +8

  • A study to evaluate the effectiveness and safety of admilparant in patients with progressive pulmonary fibrosis

    Not yet recruiting

    3 1
    Investigated Drugs:
    • ADMILPARANT
    Austria Belgium Czechia Denmark Finland France +9
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!